Bone status in adults with early-onset juvenile idiopathic arthritis following 1-year anti-TNFα therapy and discontinuation of glucocorticoids

. 2013 Aug ; 33 (8) : 2001-7. [epub] 20130201

Jazyk angličtina Země Německo Médium print-electronic

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/pmid23370856

Juvenile idiopathic arthritis (JIA) is an inflammatory disease associated with bone loss and low bone mineral density (BMD). The treatment involves disease-modifying antirheumatic drugs, glucocorticoids (GCs) and biological agents. The aim of this study was to evaluate effects of 12-month therapy with the anti-tumor necrosis factor alpha (anti-TNFα) preparations on bone mineral density (BMD) and biochemical turnover markers (BTM) in adult patients with JIA who were previously either treated or not treated with glucocorticoids (GC) and to assess effects of the discontinuation of GCs on their bone status. Nineteen adult patients (12 women, 7 men) aged 18-33 years with active JIA were prospectively enrolled to receive the anti-TNFα therapy (infliximab, etanercept or adalimumab). BMD and BTMs were determined at baseline and 1-year follow-up. The anti-TNFα therapy resulted in a significant reduction in disease activity score 28 (DAS28) and C-reactive protein (CRP) and a significant increase in BMD at the lumbar spine and total body and in serum N-terminal propeptide of type I procollagen (PINP, marker of bone formation). No significant changes in serum beta C-terminal telopeptide of type I collagen (βCTX, marker of osteoclastic bone resorption) and osteocalcin (marker of bone remodeling) were found. A significant negative correlation was observed between the change in the DAS28, CRP and serum PINP. The change in serum PINP concentrations positively correlated with the change in lumbar spine BMD. A significant increase in serum PINP was observed only in patients discontinuing GCs during the anti-TNFα treatment. After the initiation of the anti-TNFα therapy in young adults with JIA, the increase in new bone formation can be explained by discontinuation of GCs administration as the patients with the largest reduction in DAS28 and CRP probably are the ones most likely to stop GC.

Zobrazit více v PubMed

J Clin Densitom. 2008 Jan-Mar;11(1):75-91 PubMed

Arthritis Rheum. 1999 Apr;42(4):790-8 PubMed

Arthritis Rheum. 2003 Apr;48(4):1093-101 PubMed

Mol Endocrinol. 2009 Oct;23(10):1525-31 PubMed

Rheumatology (Oxford). 2003 May;42 Suppl 2:ii11-6 PubMed

Ann Rheum Dis. 2006 Aug;65(8):1044-9 PubMed

J Osteoporos. 2011 Feb 20;2011:569417 PubMed

N Engl J Med. 2000 Mar 16;342(11):763-9 PubMed

Gene. 2003 Dec 4;321:1-15 PubMed

J Bone Miner Res. 2011 Aug;26(8):1729-39 PubMed

J Rheumatol. 2002 Jun;29(6):1296-300 PubMed

Semin Arthritis Rheum. 2009 Oct;39(2):116-22 PubMed

Ann Rheum Dis. 2006 Aug;65(8):1074-9 PubMed

Cytokine Growth Factor Rev. 2004 Feb;15(1):49-60 PubMed

Adv Exp Med Biol. 2003;544:181-96 PubMed

Ann Rheum Dis. 2003 Mar;62(3):245-7 PubMed

Ann Rheum Dis. 2006 Nov;65(11):1495-9 PubMed

J Bone Miner Res. 2007 May;22(5):646-55 PubMed

Arthritis Rheum. 2000 Mar;43(3):531-40 PubMed

Arthritis Rheum. 1996 May;39(5):746-57 PubMed

Med Sci Monit. 2007 Jul;13(7):PI13-8 PubMed

Clin Gastroenterol Hepatol. 2008 Dec;6(12):1378-84 PubMed

J Rheumatol. 2007 Dec;34(12):2481-5 PubMed

Arthritis Rheum. 2006 Jun;54(6):1987-94 PubMed

Ann Intern Med. 1999 Mar 16;130(6):478-86 PubMed

Arthritis Rheum. 2003 Jan;48(1):218-26 PubMed

Arthritis Rheum. 2002 Mar;46(3):785-92 PubMed

Rheumatology (Oxford). 2005 Jun;44(6):777-80 PubMed

Arthritis Rheum. 2003 Aug;48(8):2214-23 PubMed

Bone. 2008 Apr;42(4):606-15 PubMed

J Pediatr Gastroenterol Nutr. 2011 Jan;52(1):31-7 PubMed

Rheumatology (Oxford). 2004 Jun;43 Suppl 3:iii10-iii16 PubMed

J Clin Invest. 1998 Jul 15;102(2):274-82 PubMed

J Rheumatol. 1993 Jul;20(7):1189-95 PubMed

Med Care. 1992 Jun;30(6):473-83 PubMed

J Clin Endocrinol Metab. 2006 Mar;91(3):870-7 PubMed

Lancet. 1994 Jul 2;344(8914):23-7 PubMed

Osteoporos Int. 2010 Apr;21(4):637-45 PubMed

Rev Endocr Metab Disord. 2008 Jun;9(2):107-22 PubMed

Rheumatology (Oxford). 2010 Aug;49(8):1550-8 PubMed

Lancet. 1994 Oct 22;344(8930):1105-10 PubMed

Osteoporos Int. 2000;11 Suppl 6:S2-17 PubMed

J Clin Invest. 2005 Feb;115(2):282-90 PubMed

Nat Med. 2007 Feb;13(2):156-63 PubMed

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...